Publications for Dr. Michael Dellinger

Featured Publications Legend

Featured Publications

The effects of targeting stromal and tumor cell platelet-derived growth factor receptor (PDGFR) in non-small cell lung cancer (NSCLC).

Gerber DE, Gupta P, Dellinger MT, Toombs J, Valencia I, Peyton M, Loizos N, Brekken RA J. Clin. Oncol. 2011 May 29 15_suppl 10533

Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium.

Dellinger MT, Brekken RA PLoS ONE 2011 6 12 e28947

Lymphedema-distichiasis syndrome without FOXC2 mutation: evidence for chromosome 16 duplication upstream of FOXC2.

Witte MH, Erickson RP, Khalil M, Dellinger M, Bernas M, Grogan T, Nitta H, Feng J, Duggan D, Witte CL Lymphology 2009 Dec 42 4 152-60

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.

Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA Mol. Cancer Ther. 2009 Jul 8 7 1761-71

Novel FOXC2 missense mutation identified in patient with lymphedema-distichiasis syndrome and review.

Dellinger MT, Thome K, Bernas MJ, Erickson RP, Witte MH Lymphology 2008 Sep 41 3 98-102

Results 21-25 of 25